{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:56:08Z","timestamp":1785858968984,"version":"3.56.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1097\/01.mph.0000187430.60240.09","type":"journal-article","created":{"date-parts":[[2005,11,10]],"date-time":"2005-11-10T04:06:28Z","timestamp":1131595588000},"page":"604-606","source":"Crossref","is-referenced-by-count":8,"title":["Successful Treatment of Chemoresistant Stage 3 Neuroblastoma Using Irinotecan as a Single Agent"],"prefix":"10.1097","volume":"27","author":[{"given":"Jiro","family":"Inagaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisei","family":"Kawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210227","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00043426-199121000-00002","article-title":"Long-term effects of mass screening for neuroblastoma in infancy.","volume":"13","author":"Sawada","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R2-8-20210227","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/1096-911X(20010101)36:1<160::AID-MPO1039>3.0.CO;2-G","article-title":"Observation of untreated patients with neuroblastoma detected by mass screening: a wait and see pilot study.","volume":"36","author":"Yoneda","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R3-8-20210227","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1634\/theoncologist.6-6-506","article-title":"The development of camptothecin analogs in childhood cancers.","volume":"6","author":"Bomgaars","year":"2001","journal-title":"Oncologist"},{"key":"R4-8-20210227","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1200\/JCO.1999.17.6.1815","article-title":"Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.","volume":"17","author":"Furman","year":"1999","journal-title":"J Clin Oncol"},{"key":"R5-8-20210227","first-page":"170","article-title":"Phase I trial of irinotecan (CPT-11) in children: final result.","volume":"35","author":"Vassal","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"R6-8-20210227","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00043426-200202000-00007","article-title":"Phase I study of irinotecan in pediatric patients with malignant solid tumors.","volume":"24","author":"Mugishima","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"R7-8-20210227","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1078-0432.CCR-03-0175","article-title":"Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.","volume":"10","author":"Wagner","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R8-8-20210227","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00043426-200202000-00009","article-title":"Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.","volume":"24","author":"Cosetti","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"R9-8-20210227","first-page":"32","article-title":"A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study.","volume":"7","author":"Blaney","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R10-8-20210227","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/73.2.405","article-title":"Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.","volume":"73","author":"Shimada","year":"1984","journal-title":"J Natl Cancer Inst"},{"key":"R11-8-20210227","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0140-6736(05)62326-4","article-title":"Natural history of neuroblastoma found by mass screening.","volume":"349","author":"Yamamoto","year":"1997","journal-title":"Lancet"},{"key":"R12-8-20210227","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0140-6736(91)91072-3","article-title":"Spontaneous regression of neuroblastoma detected by mass screening.","volume":"338","author":"Matsumura","year":"1991","journal-title":"Lancet"},{"key":"R13-8-20210227","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1200\/JCO.1999.17.10.3216","article-title":"Long-term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease-free for more than 66 months.","volume":"17","author":"Kawa","year":"1999","journal-title":"J Clin Oncol"},{"key":"R14-8-20210227","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pbc.20219","article-title":"High-dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.","volume":"44","author":"Pritchard","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"R15-8-20210227","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00043426-200312000-00005","article-title":"Primary tumor control in patients with stage 3\/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants.","volume":"25","author":"Marcus","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"R16-8-20210227","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.bmt.1704070","article-title":"Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation.","volume":"32","author":"Inoue","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R17-8-20210227","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0300-9084(98)80009-6","article-title":"Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.","volume":"80","author":"Vassal","year":"1998","journal-title":"Biochimie"},{"key":"R18-8-20210227","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mpo.2950230607","article-title":"Effect of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-tranplanted neuroblastoma.","volume":"23","author":"Komuro","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"R19-8-20210227","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1158\/0008-5472.CAN-03-2915","article-title":"In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.","volume":"64","author":"Santos","year":"2004","journal-title":"Cancer Res"},{"key":"R20-8-20210227","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mpo.10104","article-title":"Successful clinical response to irinotecan in relapsed neuroblastoma.","volume":"40","author":"Shitara","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"R21-8-20210227","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00043426-200212000-00014","article-title":"Novel therapeutic approaches in the treatment of children with hepatoblastoma.","volume":"24","author":"Katzenstein","year":"2002","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mph.0000187430.60240.09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:59:16Z","timestamp":1785855556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-200511000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mph.0000187430.60240.09","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}